Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of medicines for serious diseases. The company operates in a single segment with a focus on oncology, hematology, immunology, cardiovascular, and neuroscience. Key products include Opdivo, Yervoy, Orencia, Reblozyl, Breyanzi, Abecma, Camzyos, Zeposia, Sotyktu, Krazati, Cobenfy, and Eliquis. The company sells its products worldwide to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, government agencies, and directly to patients. Significant manufacturing operations are located in the U.S., Puerto Rico, the Netherlands, Ireland, and Switzerland. Bristol-Myers Squibb was incorporated in 1933 as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989 following a merger. Recent business development activities include the acquisition of Orbital Therapeutics and strategic collaborations with BioNTech and Philochem.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage bms.com
Sector Healthcare IR page bms.com/investors.html
Tags
oncology, hematology, immunology, cardiovascular, neuroscience, biologics, small molecule drugs, car-t cell therapies, antibody-drug conjugates, radiopharmaceuticals, protein degraders, Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy, Eliquis, Orbital Therapeutics, BioNTech, Philochem, RYZ101, RayzeBio, Admilparant, ZENBEXUS, iberdomide
Press page bms.com/news-and-media/press-releases

Metrics

Valuation  
Market cap $ 129.411B
Market cap (USD) $ 129.411B
P/E 14.01
PEG 3.79
P/BV 5.53
P/S 2.59
P/OCF 12.15
P/FCF 13.94
Dividend yield 4.0%
Turnover / mcap —
Returns  
ROE 40.5%
ROI 11.1%
ROIC 16.4%
Profit margin 14.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 3.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 182.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score 15.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 48.194B 48.3B 45.006B 46.159B 46.385B 42.518B 26.145B 22.561B 20.776B 19.427B 16.56B 15.879B 16.385B 17.621B 21.244B 19.484B 18.808B 20.597B 19.348B 17.914B 19.207B 19.38B 20.894B 18.119B 19.423B 18.216B 20.222B
Net profit 7.054B -8.948B 8.025B 6.327B 6.994B -9.015B 3.439B 4.92B 1.007B 4.457B 1.565B 2.004B 2.563B 1.96B 3.709B 3.102B 10.612B 5.247B 2.165B 1.585B 3B 2.388B 3.106B 2.066B 5.245B 4.711B 4.167B
Free cash flow 12.845B 13.942B 12.651B 11.948B 15.234B 13.299B 7.231B 4.989B 4.22B 1.635B 1.012B 2.622B 3.008B 6.393B 4.473B 4.067B 3.335B 2.766B 2.31B 1.298B 1.098B 2.5B 2.575B -40M 4.379B 4.063B 3.761B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 53.94 56.56 51.31 71.95 62.35 62.03 64.19 51.98 61.28 58.44 68.79 59.03 53.15 32.59 35.24 26.48 25.25 23.25 — 24.92 — — — — — — —
Price performance 12m -0.05 0.1 -0.29 0.15 0.01 -0.03 0.23 -0.15 0.05 -0.15 0.17 0.11 0.63 -0.08 0.33 0.05 0.09 — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.77B 4.35B 4.64B 6.48B 7.22B 7.98B 8.15B 8.88B 9.01B 9.59B
↳ YoY growth +28.0% +15.2% +6.6% +39.7% +11.5% +10.5% +2.2% +9.0% +1.5% +6.4%
↳ 5y CAGR +10.9% +20.5% +22.4% +25.3% +19.6% +16.2% +13.4% +13.9% +6.8% +5.8%
Borrowings, current (USD) 1.74B 811M 2.95B 6.11B 4.34B 9.71B 8.16B 5.99B 3.87B 4.24B
Borrowings, non-current (USD) 5.72B 6.98B 5.65B 43.4B 48.3B 39.6B 35.1B 36.7B 47.6B 42.9B
Lease liabilities (USD) — — 548M 805M 997M 1.04B 1.4B 1.69B 1.55B 2.03B
Cash and deposits (USD) 4.24B 5.42B 6.91B 12.3B 14.5B 14B 9.12B 11.5B 10.3B 10.2B
Intangible assets (USD) 1.39B 1.21B 1.09B 64B 53.2B 42.5B 35.9B 27.1B 23.3B 19.1B
Right-of-use assets (USD) — — 543M 704M 859M 919M 1.22B 1.39B 1.22B 1.58B
Net debt (borrowings + leases - cash) (USD) 3.22B 2.37B 1.69B 38B 38.1B 36.4B 35.5B 32.9B 42.7B 38.9B
Cash flow detail
Operating cash flow (USD) 2.85B 5.28B 5.94B 8.07B 14.1B 16.2B 13.1B 13.9B 15.2B 14.2B
Purchases of property, plant and equipment (USD) -1.22B -1.06B -951M -836M -753M -973M -1.12B -1.21B -1.25B -1.31B
Purchases of intangible assets (USD) — — — — — -300M — — — —
Change in receivables (cash effect) (USD) -803M -431M -429M 752M -646M -1.05B -663M -995M 264M -295M
Change in inventories (cash effect) (USD) -152M -29M -216M 463M 2.67B 13M -69M -751M -486M -184M
Change in payables (cash effect) (USD) 104M 320M -59M 229M 188M 245M 109M 198M 184M -2M
Dividends paid (cash effect) (USD) -2.55B -2.58B -2.61B -2.68B -4.08B -4.4B -4.63B -4.74B -4.86B -5.05B
Share buybacks (cash effect) (USD) -231M -2.47B -320M -7.3B -1.55B -6.29B -8B -5.16B 0.00 0.00
Interest paid (cash effect) (USD) -191M -215M -212M -414M -1.6B -1.5B -1.4B -1.2B -1.8B -2.1B
Income taxes paid (cash effect) (USD) -2.04B -546M -747M -1.5B -3.4B -3.5B -5.4B -4.3B -3.9B -3.26B
Share-based compensation (USD) 205M 199M 221M 441M 779M 583M 457M 518M 507M 553M
Operating cash flow before change in receivables (USD) 3.65B 5.71B 6.37B 7.32B 14.7B 17.3B 13.7B 14.9B 14.9B 14.5B
Free cash flow (OCF - PPE - intangibles) (USD) 1.64B 4.22B 4.99B 7.23B 13.3B 14.9B 11.9B 12.7B 13.9B 12.8B
Income detail
Research and development expense (USD) 4.94B 6.41B 6.35B 6.15B 11.1B 11.4B 9.51B 9.3B 11.2B 9.95B
↳ 5y CAGR +5.2% +10.4% +11.2% +6.3% +13.5% +18.1% +8.2% +7.9% +12.7% -2.2%
Total comprehensive income (USD) 4.47B 1.19B 4.79B 4.7B -9.31B 7.59B 6.33B 7.78B -8.63B 6.77B
Comprehensive income to owners (USD) 4.42B 1.22B 4.76B 4.68B -9.33B 7.57B 6.31B 7.76B -8.64B 6.77B
Provision for credit losses (USD) — — 4M 12M 12M 4M 7M 14M 41M —
Credit cost ratio (credit losses / average receivables) (%) — — 0.1% 0.2% 0.2% 0.1% 0.1% 0.2% 0.5% —
Reported Feb 21, 2017 Feb 13, 2018 Feb 10, 2021 Feb 10, 2021 Apr 29, 2021 Feb 9, 2022 Feb 14, 2023 Feb 13, 2024 Feb 12, 2025 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Download PDF Format (opens in new window)

With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30 kg with symptomatic oHCM

No patient treated with Camzyos experienced left ventricular ejection fraction (LVEF) <50% over the 56-week evaluation period, and no new safety signals were reported

Additional presentations will be shared at the American Heart Association’s Scientific Sessions 2026 that expand on the breadth of evidence supporting Camzyos across clinical and real-world settings in diverse patient populations

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, taking place November 6, 2026, in Chicago, Illinois. The SCOUT-HCM clinical trial evaluated the efficacy and safety of Camzyos (mavacamten) in pediatric patients aged 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). These additional data build upon confidence in Camzyos, which has the broadest indication of any cardiac myosin inhibitor (CMI) and is the first CMI approved for pediatric patients with symptomatic oHCM. Results from the 56-week data are consistent with previously reported 28-week results from the trial. Bristol Myers Squibb will be sharing additional presentations that add to the breadth of clinical and real-world data supporting the use of Camzyos across patient populations, reinforcing the consistent efficacy and safety profile of Camzyos as a treatment for symptomatic oHCM, at the American Heart Association’s Scientific Sessions 2026 taking place November 6 – 9, 2026, in Chicago, Illinois.

“These results are significant as they build upon the understanding of the meaningful impact of Camzyos in pediatric patients with symptomatic oHCM, evaluated in a 56-week study that included a 28-week placebo-controlled period. This is the first time a cardiac myosin inhibitor has been evaluated in this patient population for this length of time and in a double-blind study,” said Cordula Wolf, MD, Associate Professor, Technical University of Munich (TUM) University Hospital German Heart Centre. “These results serve as an important resource for healthcare providers and patients when discussing their care plan and the potential of Camzyos, the first approved treatment option for pediatric patients in the U.S. with symptomatic oHCM.”

SCOUT-HCM is a randomized, double-blind, placebo-controlled Phase 3 trial that evaluated Camzyos compared to placebo in pediatric patients aged 12 to <18 years old with symptomatic oHCM. Of the 44 randomized participants, 43 (mavacamten, n=23; placebo, n=20) completed the double-blind placebo-controlled period and entered the active treatment period. At week 28, all 43 patients who completed the double-blind placebo-controlled period were assigned Camzyos through week 56. Patients across both trial arms (mavacamten_-mavacamten and placebo-mavacamten) achieved significant reductions in Valsalva left ventricular outflow tract (LVOT) gradient. Patients in the mavacamten-_mavacamten arm experienced a mean change from baseline of -48.1 mmHg after 56 weeks of treatment. A similar degree of gradient reduction was observed in the placebo group after switching to mavacamten. Patients in both study arms showed meaningful improvements in several secondary endpoints, with no new safety signals reported.

Camzyos demonstrated a safety profile that was consistent with previously reported results for the SCOUT-HCM clinical trial, as well as previously reported Phase 3 studies evaluating Camzyos in an adult population. Treatment-related treatment-emergent adverse events (TEAEs) and serious TEAEs were low, with five and two events, respectively, reported in the mavacamten_-_mavacamten arm over 56 weeks of treatment, and one and zero events, respectively, reported in the placebo-mavacamten arm over 28 weeks of treatment. Over the 56-week period, no patient in the trial had experienced left ventricular ejection fraction (LVEF) <50%.

“Symptomatic oHCM is a serious condition for which having effective and safe treatments is crucial. These additional SCOUT-HCM results provide added confidence in Camzyos to healthcare providers as they consider treatment options for their pediatric patients with oHCM,” said Cristian Massacesi, MD , executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “BMS is committed to researching and developing new treatments to address cardiovascular disease. The data presented at these congresses helps us better understand symptomatic oHCM and the role of Camzyos in delivering more meaningful outcomes for patients and their families.”

Additional presentations at the American Heart Association’s Scientific Sessions add to the growing body of evidence supporting the efficacy and safety profile for Camzyos as a treatment option for adult patients with symptomatic oHCM. Two presentations build upon the evidence demonstrating the effectiveness and safety profile of Camzyos with long-term use. Data presented from the Camzyos Risk Evaluation and Mitigation Strategy (REMS) program after four years of follow up showed safety findings consistent with those observed in clinical trials. In a cardiac magnetic resonance (CMR) analysis of the EXPLORER cohort of the MAVA-LTE study, favorable changes in measures of cardiac structure and function were observed over up to five years of follow-up. An analysis of the EXPLORER-HCM study evaluating the impact of Camzyos treatment on a proteomic cardiovascular (CV) risk score, which has previously been reported to predict cardiovascular risk over 4 years, showed that Camzyos reduced the CV Risk SomaSignal® Test (SST) score in adult patients with oHCM. An analysis of MARVEL-HCM provided real-world insights on the impact of Camzyos use stratified by sarcomere gene variant status, with effectiveness and safety results that were consistent across variant-positive and variant-negative subgroups.

Camzyos was approved for the treatment of pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM to improve functional capacity and symptoms by the U.S. Food and Drug Administration (FDA) in September 2026. The FDA approval was based on positive 28-week results from the Phase 3 SCOUT-HCM clinical trial. Camzyos was first approved by the FDA in 2022 for the treatment of adults with symptomatic NYHA class II-III oHCM. Camzyos is supported by the largest body of worldwide evidence in the CMI treatment class.

About the Phase 3 SCOUT-HCM Trial1,2,3

SCOUT-HCM (NCT06253221 ) is a Phase 3 randomized, double-blind, placebo-controlled, international trial that enrolled 44 pediatric patients (12 years to <18 years old) with symptomatic oHCM. The trial includes three treatment periods totaling up to 200 weeks: a 28-week placebo-controlled period, followed by a 28-week active-treatment period (when patients randomized to placebo cross over to Camzyos), and an open-label long-term extension period for up to 144 weeks. At baseline, 83% and 86% of patients were receiving beta blockers, 13% and 10% were receiving calcium channel blockers, and 17% and 24% were receiving disopyramide, in the Camzyos and placebo groups, respectively. Mean LVEF was 69.0% in the Camzyos group and 67.4% in the placebo group; mean Valsalva LVOT gradient was 78 mmHg in the Camzyos group and 81 mmHg in the placebo group. Patients were randomized in a 1:1 ratio and administered either Camzyos, starting dose of 2.5 mg Camzyos for body weight 35 to <45 kg, 5 mg Camzyos for body weight ≥45 kg, or placebo, once daily for 28 weeks. Dose adjustment was based on clinical echocardiogram parameters.

The primary endpoint was change from baseline to Week 28 in Valsalva LVOT gradient (mmHg). Secondary endpoints (descriptive only) included change from baseline to Week 28 in efficacy parameters of resting and postexercise LVOT gradients, peak oxygen consumption (proportion of patients achieving an increase from baseline in pVO2), symptoms (proportion of patients with at least 1 NYHA Class improvement) and HCM Symptom Questionnaire Shortness of Breath domain (HCMSQ SoB), plus safety and pharmacokinetic parameters.

About CAMZYOS® (mavacamten)

CAMZYOS® (mavacamten) is the most extensively studied cardiac myosin inhibitor (CMI), approved by regulatory bodies in more than 60 countries and regions across five continents worldwide. CAMZYOS is supported by the largest body of worldwide evidence in the CMI treatment class, with approvals resulting from several phase III clinical trials (EXPLORER-HCM, VALOR-HCM, SCOUT-HCM, as well as HORIZON-HCM in Japan and EXPLORER-CN in China), and up to five years of follow up in multiple pivotal trial long-term extensions (EXPLORER-LTE, VALOR-HCM LTE), providing additional data on the consistent and sustained results for CAMZYOS to improve symptoms and impact cardiac structure and function.

In the U.S., CAMZYOS is indicated for the treatment of symptomatic oHCM to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. In the European Union, CAMZYOS is indicated for the treatment of symptomatic (NYHA, class II-III) oHCM in adult patients.

A selective, reversible, allosteric inhibitor of cardiac myosin, CAMZYOS targets hypercontractility, the source of oHCM. Reduction in cardiac contractility with CAMZYOS treatment leads to reduced LVOT obstruction, improved energy consumption, and lower cardiac filling pressures in oHCM patients. These effects have translated to demonstrated symptom improvements in clinical studies for adults with symptomatic oHCM, enabling them to be more active in their daily lives. CAMZYOS can be used with or without background therapies, including for newly diagnosed patients.

CAMZYOS has been prescribed by more than 5,000 healthcare providers (HCPs) to over 25,000 adult patients in the U.S. alone.

Bristol Myers Squibb: Changing the Course of Cardiovascular Disease

Bristol Myers Squibb is inspired by a single vision – transforming patients’ lives through science. Cardiovascular disease is the leading cause of death worldwide, and despite major advances in how we prevent and treat it, the human and societal burden continues to worsen over time. Whether a cardiovascular disease that affects millions of people around the world, or a rarer condition, the need is the same: new and better treatment options that allow people to continue to live their fullest lives.

Bristol Myers Squibb is committed to developing new treatments to address the global burden of cardiovascular disease. Building on our 70-year legacy of discovering and delivering paradigm-changing cardiovascular medicines, we are leveraging our experience and expertise, taking cardiovascular research to the next level and delivering meaningful, life‑changing outcomes for patients.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.

Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status.

Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of CAMZYOS is contraindicated with the following:

  • Strong CYP2C19 inhibitors
  • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers

Because of the risk of heart failure due to systolic dysfunction, CAMZYOS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CAMZYOS REMS Program.

CONTRAINDICATIONS

CAMZYOS is contraindicated with concomitant use of:

  • Strong CYP2C19 inhibitors
  • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers

WARNINGS AND PRECAUTIONS

Heart Failure

CAMZYOS reduces systolic contraction and can cause heart failure or significantly reduce ventricular function. Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, atrial fibrillation or other uncontrolled tachyarrhythmia) are at greater risk of developing systolic dysfunction and heart failure.

Assess the patient’s clinical status and LVEF prior to and regularly during treatment and adjust the CAMZYOS dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, palpitations, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be signs and symptoms of heart failure and should also prompt an evaluation of cardiac function.

Asymptomatic LVEF reduction, intercurrent illnesses, and arrhythmias require additional dosing considerations.

Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited.

CYP450 Drug Interactions Leading to Heart Failure or Loss of Effectiveness

CAMZYOS is primarily metabolized by CYP2C19 and CYP3A4 enzymes. Concomitant use of CAMZYOS and drugs that interact with these enzymes may lead to life-threatening drug interactions such as heart failure or loss of effectiveness.

Advise patients of the potential for drug interactions, including with over-the-counter medications (such as omeprazole, esomeprazole, or cimetidine). Advise patients to inform their healthcare provider of all concomitant products prior to and during CAMZYOS treatment.

CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program

CAMZYOS is only available through a restricted program called the CAMZYOS REMS Program because of the risk of heart failure due to systolic dysfunction. Notable requirements of the CAMZYOS REMS Program include the following:

  • Prescribers must be certified by enrolling in the REMS Program
  • Patients must enroll in the REMS Program and comply with ongoing monitoring requirements
  • Pharmacies must be certified by enrolling in the REMS Program and must only dispense to patients who are authorized to receive CAMZYOS
  • Wholesalers and distributors must only distribute to certified pharmacies

Further information is available at www.CAMZYOSREMS.com or by telephone at 1-833-628-7367.

Embryo-Fetal Toxicity

CAMZYOS may cause fetal toxicity when administered to a pregnant female, based on animal studies. Confirm absence of pregnancy in females of reproductive potential prior to treatment and advise patients to use effective contraception during treatment with CAMZYOS and for 4 months after the last dose. Combined hormonal contraceptives (CHCs) containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS. However, CAMZYOS may reduce the effectiveness of certain other CHCs. If these CHCs are used, advise patients to add nonhormonal contraception (such as condoms) during concomitant use and for 4 months after the last dose of CAMZYOS.

ADVERSE REACTIONS

In the EXPLORER-HCM trial, adverse reactions occurring in >5% of patients and more commonly in the CAMZYOS group than in the placebo group were dizziness (27% vs 18%) and syncope (6% vs 2%). There were no new adverse reactions identified in VALOR-HCM. The safety of CAMZYOS in pediatric patients (≥35 kg) was evaluated in SCOUT-HCM. There were no new adverse reactions compared to those identified in adult studies.

Effects on Systolic Function

In the EXPLORER-HCM trial, mean (SD) resting LVEF was 74% (6) at baseline in both treatment groups. Mean (SD) absolute change from baseline in LVEF was -4% (8) in the CAMZYOS group and 0% (7) in the placebo group over the 30-week treatment period. At Week 38, following an 8-week interruption of trial drug, mean LVEF was similar to baseline for both treatment groups. In the EXPLORER-HCM trial, 7 (6%) patients in the CAMZYOS group and 2 (2%) patients in the placebo group experienced reversible reductions in LVEF <50% (median 48%: range 35-49%) while on treatment. In all 7 patients treated with CAMZYOS, LVEF recovered following interruption of CAMZYOS.

DRUG INTERACTIONS

Potential for Other Drugs to Affect Plasma Concentrations of CAMZYOS

CAMZYOS is primarily metabolized by CYP2C19 and to a lesser extent by CYP3A4 and CYP2C9. Inducers and inhibitors of CYP2C19 and moderate to strong inhibitors or inducers of CYP3A4 may affect the exposures of CAMZYOS.

Impact of Other Drugs on CAMZYOS:

  • Strong CYP2C19 Inhibitors: Concomitant use increases CAMZYOS exposure, which may increase the risk of heart failure due to systolic dysfunction. Concomitant use is contraindicated
  • Moderate to Strong CYP2C19 Inducers or Moderate to Strong CYP3A4 Inducers: Concomitant use decreases CAMZYOS exposure, which may reduce CAMZYOS’ efficacy. The risk of heart failure due to systolic dysfunction may increase with discontinuation of these inducers as the levels of induced enzyme normalizes. Concomitant use is contraindicated
  • Weak CYP2C19 Inhibitors or Moderate CYP3A4 Inhibitors: Concomitant use with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor increases CAMZYOS exposure, which may increase the risk of adverse drug reactions. Initiate CAMZYOS at the recommended starting dosage in patients who are on stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor. Reduce dose of CAMZYOS by one level (ie, 15 mg to 10 mg, 10 mg to 5 mg, 5 mg to 2.5 mg, or 2.5 mg to 1 mg [pediatric dosing]) in patients who are on CAMZYOS treatment and intend to initiate a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor. Avoid initiation of concomitant weak CYP2C19 and moderate CYP3A4 inhibitors in patients who are on the lowest recommended dose of CAMZYOS. For short-term use (eg, 1 week), interrupt CAMZYOS for the duration of treatment with a weak inhibitor of CYP2C19 or a moderate inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy.
  • Moderate CYP2C19 Inhibitors or Strong CYP3A4 Inhibitors: Concomitant use with a moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor increases CAMZYOS exposure, which may increase the risk of adverse drug reactions. Discontinuing use of a moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor after long-term concomitant use may decrease CAMZYOS exposure, which may reduce CAMZYOS’ efficacy. Initiate CAMZYOS at one dose level below the recommended starting dose in patients who are on stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Reduce dose of CAMZYOS by one level (ie, 15 mg to 10 mg; 10 mg to 5 mg; 5 mg to 2.5 mg; or 2.5 mg to 1 mg [pediatric dosing]) in patients who are on CAMZYOS and intend to initiate a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Avoid initiation of concomitant moderate CYP2C19 and strong CYP3A4 inhibitors in patients who are on the lowest recommended dose of CAMZYOS. An increase in dose of CAMZYOS may be needed if the moderate inhibitor of CYP2C19 or strong inhibitor of CYP3A4 is discontinued after long-term concomitant use. Monitor for new or worsening symptoms. For short-term use (eg, 1 week), interrupt CAMZYOS for the duration of treatment with a moderate inhibitor of CYP2C19 or a strong inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy.

Potential for CAMZYOS to Affect Plasma Concentrations of Other Drugs

CAMZYOS is an inducer of CYP3A4, CYP2C9, and CYP2C19. Concomitant use with CYP3A4, CYP2C9, or CYP2C19 substrates may reduce plasma concentration of these drugs. Closely monitor when CAMZYOS is used with concomitant CYP3A4, CYP2C9, or CYP2C19 substrates unless otherwise recommended in the Prescribing Information.

Certain Combined Hormonal Contraceptives (CHCs): Progestin and ethinyl estradiol are CYP3A4 substrates. Concomitant use of CAMZYOS may decrease exposures of certain progestins, which may lead to contraceptive failure. CHCs containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS, but if other CHCs are used, advise patients to add nonhormonal contraception (such as condoms) or use an alternative contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) during concomitant use and for 4 months after the last dose of CAMZYOS.

Drugs That Reduce Cardiac Contractility

Expect additive negative inotropic effects of CAMZYOS and other drugs that reduce cardiac contractility. Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited.

If concomitant therapy with a negative inotrope is initiated, or if the dose of a negative inotrope is increased, monitor LVEF closely until stable doses and clinical response have been achieved.

SPECIFIC POPULATIONS

Pregnancy

CAMZYOS may cause fetal harm when administered to a pregnant female. Advise pregnant females about the potential risk to the fetus with maternal exposure to CAMZYOS during pregnancy. There is a pregnancy safety study for CAMZYOS. If CAMZYOS is administered during pregnancy, or if a patient becomes pregnant while receiving CAMZYOS or within 4 months after the last dose of CAMZYOS, healthcare providers should report CAMZYOS exposure by contacting Bristol Myers Squibb at 1-800-721-5072 or www.bms.com .

Lactation

The presence of CAMZYOS in human or animal milk, the drug’s effects on the breastfed infant, or the effects on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CAMZYOS and any potential adverse effects on the breastfed child from CAMZYOS or from the underlying maternal condition.

Females and Males of Reproductive Potential

Confirm absence of pregnancy in females of reproductive potential prior to initiation of CAMZYOS. Advise females of reproductive potential to use effective contraception during treatment with CAMZYOS and for 4 months after the last dose. CHCs containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS. However, CAMZYOS may reduce the effectiveness of certain other CHCs. If these CHCs are used, advise patients to add nonhormonal contraception (such as condoms) or use an alternative contraceptive method during concomitant use and for 4 months after the last dose of CAMZYOS.

Please see U.S. Full Prescribing Information , including Boxed WARNING.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com or follow us on LinkedIn , X , YouTube , Facebook and Instagram .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that results of future post-marketing studies will be consistent with the results of this study, that Camzyos (mavacamten) for the indication described in this release may not be commercially successful, any marketing approvals, if granted, may have significant limitations on their use, and that continued approval of Camzyos may be contingent upon verification and description of clinical benefit in additional confirmatory trials. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

References

  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2026.
  2. Rossano JW, Canter C, Wolf CM, et al. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. Published online March 29, 2026. doi:10.1056/NEJMoa2601103
  3. Rossano J, Canter C, Wolf C, et al. Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial. Am Heart J. 2026;292:107283. doi:10.1016/j.ahj.2025.107283

corporate financial-news

Bristol Myers Squibb

Media Inquiries:
[email protected]

Investors:
[email protected]

Source: Bristol Myers Squibb

Categories: Press Releases

Media downloads:

Company's logo 1497 x 206 jpg 99 KB

Download original jpg 99 KB 1497 x 206

Download thumbnail png 5 KB 200 x 28

Download lowres png 15 KB 480 x 66

Download square png 8 KB 250 x 250

BMS contacts

Media inquiries:
[email protected]

Investors relations:
[email protected]

Source: Bristol Myers Squibb

Follow us

© 2026 Bristol-Myers Squibb Company

Download PDF Format (opens in new window)

Webcast Press release (PDF) Q3 2026 Results Presentation (PDF)

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2026 financial results.

Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed third quarter 2026 earnings press release and investor presentation.

The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 29, 2026, which is accessible here . Company executives will review financial results with the investment community during the call.

A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.

**About Bristol Myers Squibb: Transforming Patients' Lives Through Science
**At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn , X , YouTube , Facebook and Instagram .

corporatefinancial-news

Download PDF Format (opens in new window)

Late-breaking results to be presented in an oral presentation at ESMO 2026

PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this patient population

Iza-bren, a potentially first-in-class dual-targeting EGFRxHER3 bispecific antibody-drug conjugate, has now demonstrated clinical benefit in five distinct tumor types

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)-- SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis in the randomized, multicenter Phase 3 PANKU-Lung01 (NCT06382116) study evaluating izalontamab brengitecan (iza-bren), an investigational, first-in-class, dual-targeting EGFRxHER3 bispecific antibody-drug conjugate (ADC), versus platinum-based chemotherapy (PBC) in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) who were previously treated with an EGFR tyrosine kinase inhibitor (TKI). Results will be presented today in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2026 Annual Congress taking place October 23 – 27 in Madrid, Spain, and simultaneously published in The Lancet.

Median follow-up for progression-free survival (PFS) was 14.6 months. Results showed iza-bren (n=216) significantly improved PFS, the study’s primary endpoint, compared to PBC (n=206), with a median PFS by Blinded Independent Central Review (BICR) of 11.1 months for iza-bren vs. 5.7 months for PBC (HR: 0.40; 95% CI: 0.31-0.51; p<0.0001). For the secondary endpoint of overall survival (OS), data were immature, though a favorable trend toward improved OS was observed with iza-bren vs. PBC. The confirmed objective response rate (cORR) by BICR was 60.2% for iza-bren vs. 34.5% for PBC, and the median duration of response (mDOR) was 10.4 months vs. 5.7 months.

“When EGFR-mutated NSCLC progresses after an EGFR TKI therapy, patients and physicians have historically had few effective treatment options, with chemotherapy often serving as the default, though it offers limited survival benefit,” said Professor Li Zhang, Chief Lung Cancer Expert, Sun Yat-sen University Cancer Center. “The PANKU-Lung01 findings suggest that iza-bren could change the trajectory of the disease, offering patients more time before their disease worsens. These results could mark an important shift in how we approach acquired resistance in this disease to significantly improve patient outcomes.”

Iza-bren showed a manageable safety profile in this population, with no new safety signals observed. Grade ≥3 treatment-related adverse events (TRAEs) were predominantly hematologic in nature. TRAEs were manageable with standard supportive care, and only 1.9% of patients in the iza-bren group discontinued treatment due to TRAEs. Interstitial lung disease (ILD) was uncommon with iza-bren (adjudicated ILD, two [0.9%]; one Grade 3 and one Grade 1).

“Post-progression EGFR-mutated NSCLC represents one of oncology's challenging treatment scenarios. With iza-bren, we achieved a nearly two-fold improvement in median PFS, along with a well-understood safety profile and high response rate. This demonstrates that dual-targeting EGFR and HER3 may fundamentally shift outcomes for these patients,” said Dr. Jonathan Cheng, chief medical officer, SystImmune. “These data validate our conviction that iza-bren addresses a critical unmet need and provides much-needed innovation for patients who often have limited options after TKI failure.”

“The PANKU-Lung01 results mark an important inflection point for iza-bren and reinforce our belief that this potentially first-in-class EGFRxHER3 bispecific ADC could, if approved, improve outcomes across the cancer treatment landscape,” said Cristian Massacesi, MD , executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “The breadth of clinical benefit now seen across five tumor types is highly encouraging and speaks to the potential of iza-bren to address significant unmet needs in oncology. We are committed to advancing iza-bren with urgency to deliver this innovative treatment option to patients.”

Iza-bren has demonstrated clinical benefit across five Phase 3 trials in five distinct indications, including previously-treated EGFR-mutated NSCLC, nasopharyngeal carcinoma after prior treatment, previously-treated esophageal squamous cell carcinoma, advanced triple-negative breast cancer and previously-treated HR+/HER2-negative breast cancer, underscoring iza-bren’s broad therapeutic potential in areas of critical unmet need. Iza-bren has also received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for previously-treated advanced EGFR-mutated NSCLC.

The PANKU-Lung01 study is sponsored by SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), in Mainland China. Outside of China, iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement.

About izalontamab brengitecan (iza-bren)

Izalontamab brengitecan (iza-bren, BL-B01D1) is a bispecific antibody-drug conjugate (ADC) that targets both EGFR and/or HER3, antigens that are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Upon target binding and internalization, iza-bren's therapeutic novel Topo1i payload is released, causing cytotoxic stress that leads to cancer cell death. Iza-bren's dual mechanism of action also blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. Iza-bren is being developed under a license and collaboration agreement by and between SystImmune and Bristol Myers Squibb.

About SystImmune

SystImmune is a clinical-stage biotechnology company located in Bothell, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development**.**

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn , X , YouTube , Facebook and Instagram .

Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that izalontamab brengitecan (iza-bren) may not achieve its primary study endpoints or receive regulatory approvals for the indications described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such treatment for such indication will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporatefinancial-news

Bristol Myers Squibb
Media Relations
[email protected]

Investor Relations
[email protected]

SystImmune
[email protected]

Source: Bristol Myers Squibb

Categories: Press Releases

Media downloads:

Company's logo 484 x 156 jpg 12 KB

Download original jpg 12 KB 484 x 156

Download thumbnail png 19 KB 200 x 64

Download lowres png 93 KB 480 x 155

Download square png 29 KB 250 x 250

BMS contacts

Media inquiries:
[email protected]

Investors relations:
[email protected]

Source: Bristol Myers Squibb

Follow us

© 2026 Bristol-Myers Squibb Company

Prompts

Bristol-Myers Squibb Company (ticker BMY), listed in United States.

Company History

Date Change Detail
Mar 14, 2024 Acquired Acquired Karuna Therapeutics, Inc. (CIK 1771917). Its filings from before the deal are on its own company page, not shown here.
Nov 6, 2023 Acquired Acquired Mirati Therapeutics, Inc. (CIK 1576263). Its filings from before the deal are on its own company page, not shown here.
Oct 31, 2019 Acquired Acquired Celgene Corp (CIK 816284). Its filings from before the deal are on its own company page, not shown here.
Aug 3, 2012 Acquired Acquired Amylin Pharmaceuticals Inc (CIK 881464). Its filings from before the deal are on its own company page, not shown here.
Nov 8, 2011 Acquired Acquired Inhibitex, Inc. (CIK 1274913). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Bristol-Myers Squibb Company

ETF Weight in ETF Shares Market value As of
CAMX 4.47% 46,557 $ 3.041M Jul 31, 2026
MEDX 4.42% 14,644 $ 843.787K Jun 30, 2026
SIXA 4.00% 364,600 $ 22.722M Nov 12, 2026
CANC 3.57% 112,924 $ 7.544M Aug 31, 2026
DIVP 3.52% 33,216 $ 1.914M Jun 30, 2026
DDDD 3.02% 3,746 $ 235.736K Nov 17, 2026
ABFL 2.88% 232,064 $ 15.156M Jul 31, 2026
ACEP 2.77% 44,563 $ 2.73M Nov 18, 2026
DIVN 2.47% 113,454 $ 7.58M Aug 31, 2026
GEND 2.29% 1,704 $ 111.288K Jul 31, 2026
HRTS 2.25% 18,719 $ 1.251M Aug 31, 2026
JDOC 2.07% 3,342 $ 205.032K Nov 17, 2026
GMOV 2.06% 33,047 $ 2.208M Aug 31, 2026
RFDA 2.03% 25,032 $ 1.672M Aug 31, 2026
QVAL 1.80% 213,306 $ 13.09M Nov 18, 2026
AQEC 1.68% 167,640 $ 9.659M Jun 30, 2026
SELV 1.64% 69,653 $ 4.013M Jun 30, 2026
JHDV 1.61% 3,401 $ 195.966K Jun 30, 2026
BDVG 1.60% 3,764 $ 216.882K Jun 30, 2026
BAMV 1.59% 27,592 $ 1.843M Aug 31, 2026
BMED 1.34% 3,058 $ 192.44K Nov 16, 2026
WBIL 1.34% 7,063 $ 406.97K Jun 30, 2026
VUS 1.25% 3,408 $ 222.576K Jul 31, 2026
ECML 1.23% 24,166 $ 1.48M Nov 18, 2026
ITAN 1.22% 24,494 $ 1.503M Nov 17, 2026
JDIV 1.21% 2,429 $ 149.019K Nov 17, 2026
GINX 1.18% 18,758 $ 1.253M Aug 31, 2026
PY 1.17% 44,645 $ 2.572M Jun 30, 2026
LSVD 1.10% 109,100 $ 7.125M Jul 31, 2026
LCF 1.03% 11,542 $ 665.05K Jun 30, 2026
HIDV 1.00% 30,838 $ 2.06M Aug 31, 2026
LVDS 0.97% 18,918 $ 1.161M Nov 17, 2026
ENHU 0.91% 1,353 $ 85.144K Nov 16, 2026
ZECP 0.91% 51,222 $ 3.422M Aug 31, 2026
BKDV 0.89% 250,811 $ 16.38M Jul 31, 2026
DUHP 0.88% 2,742,961 $ 170.941M Nov 12, 2026
BRCE 0.87% 4,839 $ 323.294K Aug 31, 2026
SHRT 0.87% 1,782 $ 112.141K Nov 17, 2026
VFVA 0.86% 122,977 $ 8.216M Aug 31, 2026
VFMF 0.85% 124,272 $ 8.303M Aug 31, 2026
LCDS 0.85% 2,210 $ 135.584K Nov 17, 2026
EBI 0.84% 86,806 $ 5.8M Aug 31, 2026
JOYT 0.82% 15,852 $ 972.52K Nov 17, 2026
LSEQ 0.80% 2,229 $ 141.385K Nov 13, 2026
JAVA 0.80% 969,444 $ 59.475M Nov 17, 2026
FEAC 0.79% 3,553 $ 204.724K Jun 30, 2026
AVIE 0.77% 2,031 $ 127.811K Nov 16, 2026
FELV 0.77% 425,418 $ 24.513M Jun 30, 2026
SEIV 0.77% 194,612 $ 11.214M Jun 30, 2026
FHEQ 0.74% 105,853 $ 6.913M Jul 31, 2026
FYEE 0.74% 24,743 $ 1.616M Jul 31, 2026
CLSE 0.73% 98,626 $ 6.589M Aug 31, 2026
DFLV 0.73% 902,549 $ 56.247M Nov 12, 2026
DVAL 0.72% 9,031 $ 520.366K Jun 30, 2026
DFVX 0.72% 66,210 $ 4.126M Nov 12, 2026
FELC 0.71% 967,212 $ 55.731M Jun 30, 2026
COPY 0.67% 42,272 $ 2.824M Aug 31, 2026
JGLO 0.66% 620,379 $ 38.06M Nov 17, 2026
DFUV 0.66% 1,655,667 $ 103.181M Nov 12, 2026
FLSP 0.66% 108,271 $ 6.239M Jun 30, 2026
CVAR 0.65% 4,281 $ 279.592K Jul 31, 2026
ROE 0.61% 24,614 $ 1.51M Nov 18, 2026
HELO 0.60% 465,920 $ 28.584M Nov 17, 2026
FTLS 0.57% 233,552 $ 0.00 Nov 16, 2026
JEPI 0.56% 4,229,669 $ 259.49M Nov 17, 2026
CAPE 0.54% 22,174 $ 1.278M Jun 30, 2026
JUSA 0.52% 74,161 $ 4.55M Nov 17, 2026
TCAL 0.52% 27,100 $ 1.705M Nov 17, 2026
PAPI 0.51% 35,650 $ 2.054M Jun 30, 2026
AFLG 0.51% 75,488 $ 4.75M Nov 16, 2026
FMDE 0.49% 630,201 $ 36.312M Jun 30, 2026
RCGE 0.49% 7,846 $ 480K Nov 18, 2026
VSLU 0.48% 45,860 $ 2.642M Jun 30, 2026
GSPY 0.48% 52,218 $ 3.286M Nov 17, 2026
LGDX 0.45% 9,731 $ 612.372K Nov 17, 2026
TVAL 0.42% 75,500 $ 4.751M Nov 17, 2026
GVLU 0.37% 15,305 $ 963.144K Nov 17, 2026
ACVF 0.33% 7,798 $ 509.287K Jul 31, 2026
STOX 0.33% 10,916 $ 729.298K Aug 31, 2026
DXUV 0.32% 325,398 $ 20.279M Nov 12, 2026
SFTY 0.32% 37,979 $ 2.537M Aug 31, 2026
ACLC 0.32% 15,456 $ 1.033M Aug 31, 2026
DFSU 0.31% 120,776 $ 7.527M Nov 12, 2026
TACU 0.30% 887 $ 55.819K Nov 17, 2026
IQSZ 0.30% 7,908 $ 516.471K Jul 31, 2026
XMAG 0.29% 10,159 $ 633.109K Nov 13, 2026
HEQQ 0.29% 1,395 $ 85.583K Nov 17, 2026
IALT 0.28% 358,740 $ 22.576M Nov 16, 2026
LDRX 0.27% 10,169 $ 679.391K Aug 31, 2026
SFGV 0.26% 49,752 $ 3.05M Nov 18, 2026
MODL 0.25% 44,766 $ 2.579M Jun 30, 2026
HELX 0.25% 1,196 $ 68.914K Jun 30, 2026
NBCR 0.24% 30,864 $ 2.062M Aug 31, 2026
AAUS 0.24% 19,744 $ 1.21M Nov 18, 2026
RGLO 0.24% 13,863 $ 798.786K Jun 30, 2026
AVSU 0.23% 17,760 $ 1.118M Nov 16, 2026
JFLI 0.23% 1,771 $ 108.651K Nov 17, 2026
JEPQ 0.22% 1,502,107 $ 92.154M Nov 17, 2026
APUE 0.22% 80,213 $ 5.359M Aug 31, 2026
ADME 0.21% 9,531 $ 622.47K Jul 31, 2026